NEOGENOMICS INC

NEO

Explore Our Financial Data > Companies > NEOGENOMICS INC

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	NEO
CIK	0001077183
SIC	8734
Sector	Services
Industry Category	Business Services
Industry Group	Services – Research, Development, Testing Labs

Contact

Address	9490 NEOGENOMICS WAY, FORT MYERS, FL, 33912
Website	neogenomics.com
Phone	2397680600
CEO	Christopher M. Smith
Employees	2,100

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$709.16 million
Pre-Tax Income	$-113.99 million
Net Income	$-113.47 million
Net Income to Common	$-113.47 million
EPS	N/A

View All

Balance Sheet

Cash	$164.12 million
Assets	$1.37 billion
Liabilities	$536.49 million
Common Equity	$838.29 million
Liabilities & Equity	$1.37 billion

View All

Cash Flow Statement

Net Income	$-113.47 million
Cash From Operating Activities	$13.69 million
Cash From Investing Activities	$-11.50 million
Cash From Financing Activities	$-200.03 million
Change in Cash	$-197.88 million

View All

Calculations

NOPAT	$-84.61 million
EBITDA	$-49.12 million
Price to Earnings	N/A
Price to Book	$1.84
ROE	-12.99%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NeoGenomics (NEO): Assessing Valuation After a 44% Three-Month Share Price Rebound

NeoGenomics (NEO) has quietly strung together a solid rebound, with shares up roughly 44% over the past 3 months and about 16% this month, drawing fresh attention after a tough year. See our latest analysis for NeoGenomics. Despite that sharp 90 day share price return, NeoGenomics is still nursing a negative year to date share price return and a weak one year total shareholder return. This suggests momentum is rebuilding from a low base as investors reassess its growth prospects. If...

Article Link

NeoGenomics to Present New ctDNA Research at SABCS 2025

FORT MYERS, Fla., December 10, 2025--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.

Article Link

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

FORT MYERS, Fla., December 08, 2025--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.

Article Link

Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how NeoGenomics (NASDAQ:NEO) and the rest of the testing & diagnostics services stocks fared in Q3.

Article Link

3 Overrated Stocks That Concern Us

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Article Link